RT Journal Article
SR Electronic
T1 Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.01.21250944
DO 10.1101/2021.02.01.21250944
A1 Saad-Roy, Chadi M.
A1 Morris, Sinead E.
A1 Metcalf, C. Jessica E.
A1 Mina, Michael J.
A1 Baker, Rachel E.
A1 Farrar, Jeremy
A1 Holmes, Edward C.
A1 Pybus, Oliver G.
A1 Graham, Andrea L.
A1 Levin, Simon A.
A1 Grenfell, Bryan T.
A1 Wagner, Caroline E.
YR 2021
UL http://medrxiv.org/content/early/2021/02/03/2021.02.01.21250944.abstract
AB As the threat of Covid-19 continues and in the face of vaccine dose shortages and logistical challenges, various deployment strategies are being proposed to increase population immunity levels. How timing of delivery of the second dose affects infection burden but also prospects for the evolution of viral immune escape are critical questions. Both hinge on the strength and duration (i.e. robustness) of the immune response elicited by a single dose, compared to natural and two-dose immunity. Building on an existing immuno-epidemiological model, we find that in the short-term, focusing on one dose generally decreases infections, but longer-term outcomes depend on this relative immune robustness. We then explore three scenarios of selection, evaluating how different second dose delays might drive immune escape via a build-up of partially immune individuals. Under certain scenarios, we find that a one-dose policy may increase the potential for antigenic evolution. We highlight the critical need to test viral loads and quantify immune responses after one vaccine dose, and to ramp up vaccination efforts throughout the world.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded in part by Open Philanthropy, the Natural Sciences and Engineering Research Council of Canada through a Postgraduate-Doctoral Scholarship (CMSR), the Cooperative Institute for Modelling the Earth System (CIMES) (REB), the James S. McDonnell Foundation 21st Century Science Initiative Collaborative Award in Understanding Dynamic and Multi-scale Systems (CMSR, SAL), the C3.ai Digital Transformation Institute and Microsoft Corporation (SAL), Gift from Google, LLC (SAL), the National Science Foundation (CNS-2027908, CCF1917819) (SAL), the U.S. CDC (BTG), Flu Lab (BTG).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe manuscript does not include new data